BioSpace News Archive

Sirnaomics Ltd. announced the Group has completed all dosing regimens for its Phase I study of STP707 for the treatment of multiple solid tumors in patients with various types of late-stage cancers who did not respond to multiple rounds of other oncology treatments.

Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

Cardinal Health announced the launch of its next generation NTrainer™ System 2.0, a medical device designed to help premature and newborn infants develop the oral coordination skills important for the transition to independent feeding faster, thus helping to reduce their neonatal intensive care unit length of stay.

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) today announced the expanded evaluation of tecarfarin for the treatment of patients with antiphospholipid syndrome (APS) who require chronic anticoagulation.

Epineuron, a clinical-stage nerve care company, announced it has successfully enrolled the first patient in the company’s pivotal trial, REGAIN™.

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that Adam Muzikant, Ph.D., the company’s Chief Business Officer, will present at the upcoming Wells Fargo Healthcare Conference in Boston at 4:30 pm ET on Wednesday, September 6, 2023.

Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium taking place August 29 to September 1 in Jerusalem.

MedX Health Corp. is pleased to announce that it is proposing to raise up to $1,500,000 by way of a Non-Brokered Private Placement of up to 21,428,571 Units at $0.07 per Unit.

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, announced clearance by the U.S. Food and Drug Administration (FDA) for the Company’s 510(k) premarket notification submission to market SUPERB™ for the treatment of acne scars.

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs.